PUBLISHER: The Business Research Company | PRODUCT CODE: 1429514
PUBLISHER: The Business Research Company | PRODUCT CODE: 1429514
Injectable drug delivery devices serve multiple routes of drug administration, including intravenous, subcutaneous, intradermal, intra-peritoneal, and intra-muscular.
The primary types of injectable drug delivery devices include conventional injectables, pre-filled syringes, auto-injectors, and pen injectors. Pre-filled syringes come with a fixed needle and contain single-dose vaccines or other medications. These devices find applications in various medical areas such as autoimmune diseases, hormonal disorders, oncology, orphan diseases, pain management, respiratory therapy, among others. Injectable drug delivery devices are utilized by a range of end-users, including hospitals and clinics, home healthcare settings, pharmaceutical and biotechnological companies, research laboratories, and others.
The injectable drug delivery devices market research report is one of a series of new reports from The Business Research Company that provides injectable drug delivery devices market statistics, including injectable drug delivery devices industry global market size, regional shares, competitors with injectable drug delivery devices market share, detailed injectable drug delivery devices market segments, market trends, and opportunities, and any further data you may need to thrive in the injectable drug delivery devices industry. This injectable drug delivery devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The injectable drug delivery devices market size has grown strongly in recent years. It will grow from $43.54 billion in 2023 to $47.46 billion in 2024 at a compound annual growth rate (CAGR) of 9.0%. The expansion observed in the historical period can be attributed to the rapid growth in the elderly population, an increase in the number of healthcare facilities, rising healthcare expenditure, growth in biologics, and an increasing awareness of self-administration.
The injectable drug delivery devices market size is expected to see strong growth in the next few years. It will grow to $61.78 billion in 2028 at a compound annual growth rate (CAGR) of 6.8%. The anticipated growth in the forecast period can be attributed to factors such as the increasing prevalence of chronic diseases, a rising demand for injectable drugs, the sudden emergence of severe infections, and a large number of drugs and vaccines in various clinical trial stages. Notable trends expected in the forecast period include a focus on developing microneedle-based drug delivery systems, investment in the research and development of self-injectable devices, manufacturing of wearable devices, production of needle-free injection systems, expansion of product lines to include prefilled syringes, improvement of digital technology in devices, manufacturing of innovative devices, and emphasis on the production of innovative auto-injectors.
The injectable drug delivery devices market is experiencing growth driven by the increasing preference for self-injection devices. These medical devices enable patients to self-administer medication in a home setting and include needle-free, auto, pen, and wearable injectors. Notable examples include BD Physioject, a disposable auto-injector by Becton, Dickinson, and Company, designed for self-injection of drugs in chronic diseases. Companies such as Abbvie, Inc., 3M, Baxter, Gerresheimer AG, and Pfizer Inc. are actively participating in the self-injections market. The advantages of self-injectables and growing awareness of self-administration contribute to the rising demand for such devices, propelling the injectable drug delivery devices market.
The growth of the injectable drug delivery devices market is further fueled by the increasing prevalence of chronic diseases. Injectable drug delivery devices offer a convenient and reliable method for administering medications over extended periods, enhancing patient adherence and improving health outcomes. The National Center for Biotechnology Information (NCBI) projects a significant increase in the global population with chronic diseases, reaching 142.66 million by 2050. This escalating prevalence is a key driver for the injectable drug delivery devices market.
Manufacturers in the injectable drug delivery devices market are placing emphasis on auto-injectors, fully automated, customizable, and reusable devices. Auto-injectors provide patients with control over injection speed, minimizing pain or discomfort. Unilife Corporation's LISA, a reusable auto-injector, offers features such as Bluetooth LE connectivity, Wi-Fi or 3G connectivity, and pre-injection drug warming. The technological advancements and new product launches in injectable drug delivery technology are expected to drive significant market growth.
Major companies in the self-injectable drug delivery devices market are innovating new products with enhanced safety systems to stay competitive. Advanced safety injectable drug delivery devices prioritize safe, effective, and reliable drug delivery subcutaneously or intravenously. West Pharmaceutical Services, Inc. launched the NovaGuard SA Pro Safety System, designed for use with prefilled ISO standard 0.5 mL and 1mL long staked-needle syringes. This safety system focuses on preventing needlestick injuries and incorporates features such as low snap-in force, prevention of pre-activation, low activation force for user comfort, and streamlined assembly. The device design simplifies glass pre-filled syringe assembly, reducing downtime and changeover time.
Major companies operating in the injectable drug delivery devices market report are Becton, Dickinson and Company, Baxter International, Gerresheimer AG, B. Braun Melsungen AG, Catalent, Inc., SkyePharma PLC, Antares Pharma, Pfizer Inc., GE Healthcare, Owen Mumford, Catalent Pharma Solutions, Philips, West Pharmaceutical Services, Inc., Alkermes, Schott AG, UCB, AstraZeneca, Johnson & Johnson, NEARMEDIC PLUS LLC, Pendant Biosciences, Siemens, H&T Presspart, B Braun, Copernicus, Ypsomed AG, 3M Company, Aptar, Congenica Ltd., Julphar, Nemera, Stryker, Roche, Nektar Therapeutics, Eli Lilly, Merck & Co. Inc., Sandoz, Sorrel Medical, Teleflex Medical, Gilero, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline, MediPrint Ophthalmics, Medtronic, Novartis, Pharmasyntez, Bayer, Mylan N.V, Aptalis Pharma, Inc., Sanofi, Novo Nordisk, Bilim Pharmaceuticals, Battelle Medical Devices, Caplin Steriles Limited, Abbot, Allergan, Boehringer Ingelheim, Hovione Technology, Jiangsu Delfu Medical Device Co, Ltd., Syqe Medical, Terumo Corporation, Kedalion Therapeutics, Amgen Inc.
North America was the largest region in the injectable drug delivery devices market in 2023. Western Europe was the second-largest region in the global injectable drug delivery devices market. The regions covered in the injectable drug delivery devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The countries covered in the injectable drug delivery devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain
The injectable drug delivery devices market consists of sales of conventional syringes, needle-free injectors, auto-injectors, and pen injectors. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Injectable Drug Delivery Devices Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on injectable drug delivery devices market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for injectable drug delivery devices? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The injectable drug delivery devices market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
The impact of higher inflation in many countries and the resulting spike in interest rates.
The continued but declining impact of covid 19 on supply chains and consumption patterns.